Biocon Biologics, one of India's leading biologic drug manufacturers, announced on Friday the results of a Phase-3 study on a ...

Optimizing use of topical agents begins with defining "mild or moderate." Clinical trials in psoriasis employ objective ...

Patients treated with ESK-001 for moderate to severe plaque psoriasis experienced positive clinical responses through a year, ...

Until about 20 years ago, systemic treatment options for moderate/severe psoriasis were limited and nonspecific. To get an ...

More than half of patients with fingernail psoriasis achieved complete fingernail clearance after 68 weeks of guselkumab treatment.

A 40-year-old Hispanic man presented for treatment of dermatitis on his elbows ... A clinical diagnosis was made of psoriasis and he was prescribed clobetasol propionate ointment with salicylic ...

This study of the efficacy and cost-effectiveness of moderate to severe psoriasis treatments compared phototherapy, oral systemic agents, and biologics from a managed health care systems perspective.

Mar. 3, 2025 — Psoriasis is one of the most common chronic inflammatory skin diseases, affecting around 250,000 people in Austria. While previous treatment approaches have mainly focused on ...

Two posters presented at the 2025 American Academy of Dermatology Annual Meeting highlighted the importance of improving ...

Five-year data from Phase III trials demonstrated that 67.7% of patients moderate-to-severe plaque psoriasis treated with UCB ...

Tildrakizumab showed early and sustained effectiveness and quality of life (QOL) improvements in patients with moderate to ...